[S-21] シンポジウム21 Novel molecular target drugs for MG: How should we use them?

[S-21-2] 新規重症筋無力症治療：胎児性Fc受容体阻害薬

^○鵜沢 顕之 (千葉大学大学院医学研究院 脳神経内科学)

EDUCATION
1997-2003 M.D., School of Medicine, Ryukyu University
2008-2012 Ph.D. in Neurology, Graduate School of Medicine, Chiba University

CAREER
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008-2012 Department of Neurology, Chiba University Hospital
2012 to present Department of Neurology, Graduate School of Medicine, Chiba University

SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)

AWARDS
2018 Best Oral Presentation Award, Annual Meeting of the Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement